Pomerantz LLP investigates Acadia Pharmaceuticals for potential securities fraud.

Pomerantz LLP is investigating claims against ACADIA Pharmaceuticals Inc. regarding potential securities fraud and unlawful business practices. The investigation concerns the company's Phase 3 COMPASS PWS trial results, which showed that intranasal carbetocin (ACP-101) did not demonstrate a statistically significant improvement over placebo for patients with hyperphagia in Prader-Willi syndrome. Investors who have invested in Acadia are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.